Litcius/Paper detail

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes

Elaine M. Walsh, Neha Mangini, John H. Fetting, Deborah K. Armstrong, Isaac S. Chan, Roisín M. Connolly, Katie Fiallos, Jennifer Lehman, Raquel Nunes, Dana Petry, Jeffrey Reynolds, Mirat Shah, Karen L. Smith, Kala Visvanathan, Josh Lauring, Ben Ho Park, Vered Stearns, Antonio C. Wolff

2021Clinical Breast Cancer14 citationsDOI

Topics & Concepts

OlaparibMedicineBreast cancerPARP inhibitorGermline mutationOncologyInternal medicineGermlineCancer researchCancerMutationPoly ADP ribose polymeraseGeneticsGeneBiologyPolymerasePARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies
Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes | Litcius